How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease?
Sign Up to like & getrecommendations! Published in 2022 at "Transfusion"
DOI: 10.1111/trf.17038
Abstract: High titers of cold agglutinins jeopardize the quality of an apheresis product meant for autologous or allogeneic transplant. Management of transplant patients with cold agglutinin disease (CAD) is often experience‐based and under reported, yet decisions… read more here.
Keywords: cell; agglutinin disease; warm hpc; viability ... See more keywords